Exchange & Returns Information
Review Details
(0)
| Generic For | PROLIA |
|---|---|
| Active Ingredient | DENOSUMAB |
| Strength | 120MG |
| Manufacturer | CIPLA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 942.00 | $ 942.00 |
$ 800.70
Apply ZARVY26 (-15%)
You save $ 141.30
|
||
| 2 BOXES - 2 VIALS | $ 896.00 |
5% $ 1,884.00
$ 1,792.00
|
$ 1,523.20
Apply ZARVY26 (-15%)
You save $ 268.80
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 897.33 |
5% $ 2,826.00
$ 2,692.00
|
$ 2,288.20
Apply ZARVY26 (-15%)
You save $ 403.80
|
Reference information will be available soon.
Denoci 120 is a subcutaneous injectable formulation containing denosumab 120mg, a fully human monoclonal antibody that selectively targets RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).
As a potent anti-resorptive agent, Denoci 120 prevents the formation, function, and survival of osteoclasts—the cells responsible for bone degradation. This mechanism makes it highly effective in reducing skeletal-related events (SREs) in patients with bone metastases from solid tumors such as breast, prostate, and lung cancer.
It also plays a vital role in the management of giant cell tumor of bone (GCTB), especially when surgical intervention is not feasible.
Unlike bisphosphonates, denosumab does not accumulate in bone and is not cleared renally, making it suitable for patients with compromised kidney function. Denoci 120 delivers consistent suppression of bone turnover, thereby helping to preserve skeletal integrity in both oncologic and skeletal fragility contexts.
AntiCancer Drugs > Bone Metastases from Solid Tumors
Indicated for the prevention of skeletal-related events (SREs) in patients with metastatic bone disease from solid tumors. Denosumab reduces risks of pathological fractures, spinal cord compression, and the need for radiation or surgery to bone by inhibiting RANKL and osteoclast activity.
AntiCancer Drugs > Giant Cell Tumor of Bone (GCTB)
Used in adults and skeletally mature adolescents with unresectable or high-morbidity risk GCTB. Denosumab suppresses the osteoclast-like giant cells within the tumor environment, preventing bone destruction and reducing tumor progression.
DISEASES/SYMPTOMS > Postmenopausal Osteoporosis
Though the 120mg formulation is primarily for oncologic use, lower doses (60mg) of denosumab are also used in osteoporosis. It improves bone mineral density (BMD) and lowers fracture risk in postmenopausal women, especially in those intolerant to or who have failed bisphosphonate therapy.
DISEASES/SYMPTOMS > Glucocorticoid-Induced Osteoporosis
Effective in preserving bone mass in patients on chronic corticosteroids, which accelerate bone loss. Denosumab offers an alternative to bisphosphonates with less renal toxicity.
Denosumab inhibits the RANKL pathway, a key signaling mechanism in osteoclast development and bone resorption. By binding to RANKL, denosumab prevents its interaction with RANK receptors on osteoclast precursors and mature osteoclasts, thereby reducing bone turnover.
This mechanism is particularly beneficial in cancer patients with bone metastases, where excessive osteoclastic activity leads to skeletal fragility and complications. In GCTB, it reduces osteolytic lesions by neutralizing the tumor-induced bone remodeling cascade.
Denosumab’s pharmacodynamics allow for powerful and sustained suppression of bone resorption with subcutaneous administration once every four weeks, delivering high therapeutic value with predictable outcomes.
Osteoporosis (Adults)
→ Prolia (60 mg): subcutaneous injection every 6 months
→ Co-administer with calcium 1000 mg/day and vitamin D ≥400 IU/day
→ Indicated for postmenopausal women, men at high fracture risk, and patients on steroids or cancer therapies affecting bone metabolism
Giant Cell Tumor of Bone (≥13 years, skeletally mature)
→ Loading Phase: 120 mg subcutaneously on days 1, 8, and 15
→ Maintenance Dose: 120 mg subcutaneously every 4 weeks
→ Ensure sufficient calcium and vitamin D supplementation
→ Ideal for patients where surgery is not an option or would cause significant morbidity
Bone Metastases from Solid Tumors
→ Xgeva regimen: 120 mg subcutaneously every 4 weeks
→ Co-administer with calcium and vitamin D
→ Helps prevent SREs in patients with breast, prostate, lung cancer, or multiple myeloma involving bone
Hypercalcemia of Malignancy
→ Loading Dose: 120 mg subcutaneously on days 1, 8, and 15
→ Maintenance: 120 mg every 4 weeks
→ Indicated for bisphosphonate-refractory cases
→ Serum calcium monitoring is essential before and during treatment
Administration Notes
→ Administer via subcutaneous injection in the upper arm, upper thigh, or abdomen
→ Do not shake or freeze the vial
→ Rotate injection sites to minimize local irritation
→ Ensure adequate supplementation and hydration before starting therapy
Store in a refrigerator at 2°C to 8°C
Do not freeze
Keep the prefilled syringe or vial in its original packaging to protect from light
If removed from refrigeration, it can be kept at room temperature (up to 25°C) for up to 14 days
Keep out of reach of children
Common: Back pain, fatigue, constipation, bone pain, extremity pain
Less Common: Hypocalcemia, musculoskeletal stiffness, dyspnea, rashes
Rare but Serious: Osteonecrosis of the jaw (ONJ), atypical femoral fractures, severe hypocalcemia, infections
Patient Guidance: Report immediately if experiencing jaw pain, non-healing mouth sores, thigh/groin pain, or numbness/tingling in limbs
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
